Seeking Alpha on MSN4d
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
Why Did Merck Stock Rise 65%?
In this photo illustration, the Merck & Co., Inc. logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor ...
FiercePharma7d
ESMO: Even after unique trial win, Incyte CEO views PD-1 drug Zynyz as pipeline aide
Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...
Pharmabiz3d
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM
Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...
Does Adjuvant Therapy Prevent Cancer Recurrence?
Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...
Nasdaq22d
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
These setbacks are also a blow to the company’s plans to expand Keytruda’s label further ahead of the loss of exclusivity post-2028. In the past 60 days, estimates for Bioventus’ 2024 ...